stoxline Quote Chart Rank Option Currency Glossary
  
AbbVie Inc. (ABBV)
175.27  6.07 (3.59%)    07-17 16:00
Open: 169.51
High: 175.74
Volume: 6,815,764
  
Pre. Close: 169.2
Low: 169.51
Market Cap: 309,504(M)
Technical analysis
2024-07-17 5:25:14 PM
Short term     
Mid term     
Targets 6-month :  205.26 1-year :  239.74
Resists First :  175.74 Second :  205.26
Pivot price 168.96
Supports First :  168.18 Second :  163.52
MAs MA(5) :  170.53 MA(20) :  169.59
MA(100) :  169.34 MA(250) :  159.1
MACD MACD :  1.1 Signal :  0.8
%K %D K(14,3) :  64.8 D(3) :  58.7
RSI RSI(14): 63.2
52-week High :  182.88 Low :  135.85
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ABBV ] has closed Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 175.96 - 176.61 176.61 - 177.13
Low: 167.77 - 168.58 168.58 - 169.23
Close: 174.03 - 175.31 175.31 - 176.33
Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Headline News

Thu, 18 Jul 2024
AbbVie (ABBV) Set to Announce Quarterly Earnings on Thursday - Defense World

Wed, 17 Jul 2024
AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note (NYSE:ABBV) - Seeking Alpha

Tue, 16 Jul 2024
AbbVie invests in Sionna as part of licensing deal (NYSE:ABBV) - Seeking Alpha

Mon, 15 Jul 2024
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU - Zacks Investment Research

Mon, 15 Jul 2024
GSA Capital Partners LLP Sells 3,696 Shares of AbbVie Inc. (NYSE:ABBV) - Defense World

Thu, 27 Jun 2024
AbbVie Acquires Celsius Therapeutics - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 1,770 (M)
Shares Float 1,760 (M)
Held by Insiders 0.1 (%)
Held by Institutions 72.6 (%)
Shares Short 15,250 (K)
Shares Short P.Month 15,930 (K)
Stock Financials
EPS 3.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.53
Profit Margin 11 %
Operating Margin 28.2 %
Return on Assets (ttm) 7.7 %
Return on Equity (ttm) 56.2 %
Qtrly Rev. Growth 0.6 %
Gross Profit (p.s.) 0
Sales Per Share 30.73
EBITDA (p.s.) 14.75
Qtrly Earnings Growth 496.3 %
Operating Cash Flow 22,690 (M)
Levered Free Cash Flow 23,610 (M)
Stock Valuations
PE Ratio 52.16
PEG Ratio 2.3
Price to Book value 38.69
Price to Sales 5.7
Price to Cash Flow 13.67
Stock Dividends
Dividend 1.54
Forward Dividend 0
Dividend Yield 0.8%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android